ReviewBritish journal of clinical pharmacology2015
The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.
Review in British journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 6 syntheses or guidelines pooled it, 246 citations in OpenAlex.
- Diabetes risk in HIV infection and antiretroviral therapy: A systematic review and meta-analysis of prospective cohort evidence.HIV medicine · 2026Pooled it
- HIV and cardiovascular diseases: a systematic review and comparative risk assessment study.BMJ global health · 2026Pooled it
- Comprehensive Meta-Analysis on the Impact of theCurrent pharmaceutical design · 2026Pooled it
- Effectiveness of health education in improving treatment adherence among patients with chronic communicable diseases: A systematic review and meta-analysis.Tropical medicine & international health : TM & IH · 2025Pooled it
- Association between integrase strand transfer inhibitor use with insulin resistance and incident diabetes mellitus in persons living with HIV: a systematic review and meta-analysis.BMJ open diabetes research & care · 2023Pooled it
- Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.British journal of clinical pharmacology · 2018Pooled it
- Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial.AIDS (London, England) · 2026Trial
- Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration.Open forum infectious diseases · 2024Trial
- INcentives and ReMINDers to Improve Long-Term Medication Adherence (INMIND): impact of a pilot randomized controlled trial in a large HIV clinic in Uganda.Journal of the International AIDS Society · 2024Trial
- Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV.Antimicrobial agents and chemotherapy · 2021Trial
- Article
- The Effects of Compulsory Licensing: A Case Study of HIV Drugs.Health economics · 2026Article
- Establishment of an in vitro human blood-brain barrier model for antiviral screening against neurotropic viruses.Fluids and barriers of the CNS · 2026Article
- Meeting Patients with Hepatitis C Where They Are: Lessons from the HIV Epidemic in the USA.Journal of general internal medicine · 2026Article
- Hospitalization Rates and Associated Factors Among Older Adults With HIV in the United States.Journal of acquired immune deficiency syndromes (1999) · 2026Article
- Years gained, health lost? A population-based cohort study of sex differences in healthy life expectancy among people living with HIV.BMJ open · 2026Article
- Body Mass Index and Vaccine-induced Immune Responses in Children Living With HIV.The Pediatric infectious disease journal · 2026Article
- Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens.AIDS (London, England) · 2026Observational
- Exploring the impact of Cabotegravir-Rilpivirine long-acting on weight gain, body composition and quality of life in adults living with HIV.HIV medicine · 2026Article
- Antiretroviral Therapy Switching Among People with HIV in the United States is not Uncommon Despite Virologic Suppression: An OPERA Cohort Study.Infectious diseases and therapy · 2026Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The evolution of human immunodeficiency virus (HIV) treatment has improved our understanding and management of complex pharmacological issues that have driven improved outcomes and quality of life of the HIV-infected patient. These issues include adherence, long- and short-term toxicities, pharmacoenhancement, pharmacogenomics, therapeutic drug monitoring, differential penetration of drugs into sanctuary sites, such as the central nervous system, genital tract and small bowel, and drug-drug and drug-food interactions related to cytochrome P450 drug-metabolizing enzymes, uridine diphosphate glucuronyltransferases and drug transporters, to name a few. There is future promise, as an increased understanding of the immunopathogenesis of HIV and global public health initiatives are driving novel treatment approaches with goals to prevent, control and, ultimately, eradicate HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.